Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy

Therapeutic Apheresis and DialysisEarly View LETTER TO THE EDITOR Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy Michel Jadoul, Corresponding Author Michel Jadoul [email protected] orcid.org/0000-0001-7369-7812 Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium Correspondence Michel Jadoul, Division of Nephrology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, B-1200 Brussels, Belgium. Email: [email protected]Search for more papers by this authorLaura Labriola, Laura Labriola Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this author Michel Jadoul, Corresponding Author Michel Jadoul [email protected] orcid.org/0000-0001-7369-7812 Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium Correspondence Michel Jadoul, Division of Nephrology, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, B-1200 Brussels, Belgium. Email: [email protected]Search for more papers by this authorLaura Labriola, Laura Labriola Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, BelgiumSearch for more papers by this author First published: 04 September 2023 https://doi.org/10.1111/1744-9987.14060Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Toyoda H, Kikuchi K. Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy. Ther Apher Dial. 2023; 27(5): 831–838. https://doi.org/10.1111/1744-9987.14003 2Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019; 15(2): 73–86. https://doi.org/10.1038/s41581-018-0081-8 3Martin P P, Awan AA, Berenguer MC, Bruchfeld A A, Fabrizi F, Goldberg DS, et al. Executive summary of the KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2022; 102(6): 1228–1237. https://doi.org/10.1016/j.kint.2022.07.012 4Jadoul M, Bieber B, Martin P, Akiba T, Nwankwo C, Arduino JM, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019; 95(4): 939–947. https://doi.org/10.1016/j.kint.2018.11.038 5Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996; 11(Suppl 4): 36–38. https://doi.org/10.1093/ndt/11.supp4.36 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation